

# Manuel Hidalgo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4198699/publications.pdf>

Version: 2024-02-01

241  
papers

40,524  
citations

5268

83  
h-index

2448

197  
g-index

247  
all docs

247  
docs citations

247  
times ranked

42630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. <i>New England Journal of Medicine</i> , 2013, 369, 1691-1703.	27.0	5,097
2	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. <i>Science</i> , 2008, 321, 1801-1806.	12.6	3,755
3	Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1605-1617.	27.0	2,474
4	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	27.0	1,483
5	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. <i>Cancer Discovery</i> , 2014, 4, 998-1013.	9.4	1,341
6	Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2007, 25, 3230-3237.	1.6	1,109
7	Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2001, 19, 3267-3279.	1.6	981
8	<i>DPC4</i> Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1806-1813.	1.6	976
9	Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4548-4554.	1.6	957
10	Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 909-918.	1.6	948
11	Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2004, 22, 77-85.	1.6	753
12	Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2001, 93, 178-193.	6.3	732
13	Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5294-5304.	1.6	688
14	The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. <i>Oncogene</i> , 2000, 19, 6680-6686.	5.9	561
15	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	28.4	527
16	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 319-334.	27.6	489
17	An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4652-4661.	7.0	407
18	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. <i>Pancreatology</i> , 2015, 15, 8-18.	1.1	404

#	ARTICLE	IF	CITATIONS
19	Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2010, 102, 340-351.	6.3	392
20	Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity. <i>Clinical Cancer Research</i> , 2004, 10, 8059-8067.	7.0	376
21	Nodal/Activin Signaling Drives Self-Renewal and Tumorigenicity of Pancreatic Cancer Stem Cells and Provides a Target for Combined Drug Therapy. <i>Cell Stem Cell</i> , 2011, 9, 433-446.	11.1	366
22	A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1311-1316.	4.1	354
23	Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2003, 95, 851-867.	6.3	349
24	Evaluation of BCGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 157-165.	1.6	345
25	Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital. <i>Journal of Clinical Oncology</i> , 2008, 26, 3503-3510.	1.6	343
26	Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 1331-1335.	8.2	342
27	Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer. <i>Gastroenterology</i> , 2009, 137, 1102-1113.	1.3	312
28	Examining the utility of patient-derived xenograft mouse models. <i>Nature Reviews Cancer</i> , 2015, 15, 311-316.	28.4	300
29	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	30.7	297
30	Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. <i>Clinical Cancer Research</i> , 2007, 13, 3731-3737.	7.0	283
31	Pancreatic cancer. <i>Current Problems in Cancer</i> , 2002, 26, 176-275.	2.0	268
32	A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 310-314.	4.1	250
33	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 108-123.	27.6	244
34	An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors. <i>Cancer Research</i> , 2004, 64, 9139-9143.	0.9	242
35	Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 3-8.	4.1	238
36	MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts. <i>Clinical Cancer Research</i> , 2011, 17, 2799-2806.	7.0	237

#	ARTICLE	IF	CITATIONS
37	Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1739-1742.	6.3	232
38	A Phase I and Pharmacokinetic Study of Temozolomide (CC-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5755-5763.	7.0	213
39	Tumor-Initiating Cells Are Rare in Many Human Tumors. <i>Cell Stem Cell</i> , 2010, 7, 279-282.	11.1	205
40	Tumor Engraftment in Nude Mice and Enrichment in Stroma-Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5793-5800.	7.0	204
41	Convergent structural alterations define SWI/SNF chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E252-9.	7.1	192
42	Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 5386-5403.	1.6	191
43	Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. <i>Cancer Biology and Therapy</i> , 2007, 6, 432-438.	3.4	177
44	Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. <i>Journal of Clinical Oncology</i> , 2013, 31, 4445-4452.	1.6	170
45	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. <i>Nature Methods</i> , 2014, 11, 1161-1169.	19.0	170
46	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. <i>Clinical Cancer Research</i> , 2015, 21, 2325-2337.	7.0	170
47	Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2008, 7, 1146-1156.	3.4	165
48	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. <i>Nature Medicine</i> , 2016, 22, 270-277.	30.7	150
49	Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells. <i>PLoS ONE</i> , 2013, 8, e76518.	2.5	147
50	A Randomized, Phase II Trial of Two Dose Levels of Temozolomide (CC-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500). <i>Journal of Thoracic Oncology</i> , 2007, 2, 1036-1041.	1.1	145
51	Development of the epidermal growth factor receptor inhibitor OSI-774. <i>Seminars in Oncology</i> , 2003, 30, 23-31.	2.2	143
52	Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival. <i>Clinical Cancer Research</i> , 2006, 12, 2492-2497.	7.0	141
53	Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. <i>Clinical Cancer Research</i> , 2014, 20, 2476-2484.	7.0	140
54	Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 2252-2260.	1.6	138

#	ARTICLE	IF	CITATIONS
55	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 <sup>−/−</sup> /IL2R <sup>β</sup> null Immunodeficient Mice. <i>Cancer Research</i> , 2015, 75, 3466-3478.	0.9	137
56	Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1758-1771.	4.1	135
57	Characterizing DNA methylation patterns in pancreatic cancer genome. <i>Molecular Oncology</i> , 2009, 3, 425-438.	4.6	133
58	Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. <i>Cancer Biology and Therapy</i> , 2005, 4, 548-554.	3.4	132
59	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. <i>Cancer Research</i> , 2015, 75, 3355-3364.	0.9	129
60	Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. <i>Cancer Letters</i> , 2013, 335, 41-51.	7.2	125
61	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. <i>Gut</i> , 2015, 64, 1936-1948.	12.1	123
62	[ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 2697-2704.	1.6	119
63	Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology. <i>American Journal of Pathology</i> , 2003, 163, 217-229.	3.8	117
64	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. <i>Clinical Cancer Research</i> , 2015, 21, 4811-4818.	7.0	117
65	CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. <i>Cancer Cell</i> , 2020, 37, 340-353.e6.	16.8	114
66	Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. <i>Gut</i> , 2015, 64, 1921-1935.	12.1	112
67	COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3914-3924.	1.6	111
68	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	110
69	A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. <i>Cancer Biology and Therapy</i> , 2009, 8, 2013-2024.	3.4	108
70	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. <i>Cancer Research</i> , 2005, 65, 3003-3010.	0.9	105
71	Mycophenolate mofetil: An update. <i>Drugs of Today</i> , 2009, 45, 521.	1.1	105
72	Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 5504-5510.	1.6	104

#	ARTICLE	IF	CITATIONS
73	Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. <i>Cancer Biology and Therapy</i> , 2011, 12, 598-609.	3.4	103
74	CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1714-1723.	6.3	102
75	The Hedgehog Pathway and Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 2094-2096.	27.0	102
76	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. <i>Cell</i> , 2021, 184, 4753-4771.e27.	28.9	99
77	Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. <i>Cancer</i> , 2004, 101, 1609-1615.	4.1	95
78	Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 6517-6522.	7.0	95
79	A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 292-299.	2.8	95
80	Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462	2.6	92
81	Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer. <i>Cancer Research</i> , 2008, 68, 2841-2849.	0.9	89
82	Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells. <i>Clinical Cancer Research</i> , 2009, 15, 6519-6528.	7.0	88
83	A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry. <i>PLoS ONE</i> , 2012, 7, e43842.	2.5	88
84	Inhibition of Ataxia Telangiectasia- and Rad3 -Related Function Abrogates the In Vitro and In Vivo Tumorigenicity of Human Colon Cancer Cells Through Depletion of the CD133+ Tumor-Initiating Cell Fraction. <i>Stem Cells</i> , 2011, 29, 418-429.	3.2	84
85	New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. <i>Breast Cancer Research</i> , 2004, 6, 219-24.	5.0	83
86	Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 787-796.	4.1	83
87	Fenugreek: A naturally occurring edible spice as an anticancer agent. <i>Cancer Biology and Therapy</i> , 2009, 8, 272-278.	3.4	83
88	A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2582-2592.	4.1	83
89	Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva). <i>Seminars in Oncology</i> , 2003, 30, 25-33.	2.2	81
90	Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774). <i>Clinical Cancer Research</i> , 2004, 10, 6522-6527.	7.0	81

#	ARTICLE	IF	CITATIONS
91	Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 4138-4146.	7.0	79
92	Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. <i>Journal of Clinical Oncology</i> , 2012, 30, e45-e48.	1.6	79
93	The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1999-2009.	4.1	79
94	HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. <i>Journal of Clinical Pathology</i> , 2012, 65, 751-757.	2.0	78
95	Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3275-3284.	4.1	77
96	Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 178-178.	1.6	76
97	Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. <i>Clinical Cancer Research</i> , 2017, 23, 5639-5647.	7.0	76
98	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. <i>International Journal of Cancer</i> , 2018, 143, 2053-2064.	5.1	76
99	Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. <i>Cancer Cell</i> , 2019, 35, 573-587.e6.	16.8	75
100	First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study. <i>Oncologist</i> , 2012, 17, 339-345.	3.7	72
101	Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas. <i>Clinical Cancer Research</i> , 2012, 18, 4249-4256.	7.0	71
102	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. <i>Investigational New Drugs</i> , 2006, 24, 291-297.	2.6	70
103	Personalized RNA Medicine for Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1734-1747.	7.0	67
104	Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. <i>Journal of Clinical Oncology</i> , 2019, 37, 230-238.	1.6	66
105	PDX-derived organoids model in vivo drug response and secrete biomarkers. <i>JCI Insight</i> , 2020, 5, .	5.0	66
106	Pharmacodynamic-Guided Modified Continuous Reassessment Method-Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 4172-4179.	1.6	63
107	Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 793, 413-420.	2.3	61
108	Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 73-80.	2.3	61

#	ARTICLE	IF	CITATIONS
109	A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties. <i>Clinical Cancer Research</i> , 2004, 10, 6512-6521.	7.0	60
110	Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. <i>PLoS ONE</i> , 2014, 9, e107200.	2.5	58
111	The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5572-5579.	7.0	56
112	The epidermal growth factor receptor: A new target for anticancer therapy. <i>Current Problems in Cancer</i> , 2002, 26, 114-164.	2.0	54
113	Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. <i>Oncogene</i> , 2021, 40, 1393-1395.	5.9	53
114	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2462-2470.	7.0	51
115	Development of The Epidermal Growth Factor Receptor Inhibitor Tarcevatm(Osi-774). <i>Advances in Experimental Medicine and Biology</i> , 2003, 532, 235-246.	1.6	50
116	Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5281-5289.	7.0	49
117	SPARC-Independent Delivery of <i>Nab</i> -Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 680-688.	4.1	49
118	Angiogenesis inhibitors in clinical development for lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 66-77.	2.2	48
119	A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 846, 1-7.	2.3	46
120	A Fine-Needle Aspirate-Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 311-318.	4.1	46
121	Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. <i>Oncotarget</i> , 2012, 3, 1416-1427.	1.8	46
122	An Introduction to Pancreatic Adenocarcinoma Genetics, Pathology and Therapy. <i>Cancer Biology and Therapy</i> , 2002, 1, 607-613.	3.4	44
123	Panitumumab, a Monoclonal Anti-Epidermal Growth Factor Receptor Antibody in Colorectal Cancer: Another One or the One?: Table 1.. <i>Clinical Cancer Research</i> , 2007, 13, 4664-4666.	7.0	44
124	Stromal Cell-Derived Factor 1± Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer. <i>Neoplasia</i> , 2012, 14, 690-IN6.	5.3	44
125	SMURF1 Amplification Promotes Invasiveness in Pancreatic Cancer. <i>PLoS ONE</i> , 2011, 6, e23924.	2.5	44
126	<i>GPX3</i> promoter methylation predicts platinum sensitivity in colorectal cancer. <i>Epigenetics</i> , 2017, 12, 540-550.	2.7	43



#	ARTICLE	IF	CITATIONS
127	Activated Epidermal Growth Factor Receptor as a Novel Target in Pancreatic Cancer Therapy. <i>Journal of Proteome Research</i> , 2008, 7, 4651-4658.	3.7	42
128	Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. <i>Investigational New Drugs</i> , 2010, 28, 334-342.	2.6	42
129	Benzoylphenylurea Sulfur Analogues with Potent Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2357-2360.	6.4	41
130	Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2012, 18, 1051-1062.	7.0	41
131	Transcriptional dissection of pancreatic tumors engrafted in mice. <i>Genome Medicine</i> , 2014, 6, 27.	8.2	41
132	The V599E BRAF mutation is uncommon in biliary tract cancers. <i>Modern Pathology</i> , 2004, 17, 1386-1391.	5.5	40
133	Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1484-1493.	4.1	39
134	Approach to early-onset colorectal cancer: Clinicopathological, familial, molecular and immunohistochemical characteristics. <i>World Journal of Gastroenterology</i> , 2010, 16, 3697.	3.3	39
135	Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. <i>Histopathology</i> , 2011, 59, 8-17.	2.9	39
136	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1002-1009.	7.0	39
137	Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 115, 442-453.	6.4	39
138	Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties. <i>Journal of Clinical Oncology</i> , 2001, 19, 2937-2947.	1.6	38
139	Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 708-718.	7.0	38
140	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5020-5027.	7.0	37
141	C-fos Assessment as a Marker of Anti-EGFR Effect. <i>Cancer Research</i> , 2006, 66, 2385-2390.	0.9	36
142	Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. <i>Cancer Biology and Therapy</i> , 2005, 4, 1381-1386.	3.4	35
143	Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 423-433.	2.3	35
144	Phase 2 Study of Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy in Patients With Resectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 678-685.	0.8	35

#	ARTICLE	IF	CITATIONS
145	Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel. <i>Journal of Clinical Oncology</i> , 2001, 19, 2493-2503.	1.6	34
146	Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. <i>PLoS ONE</i> , 2013, 8, e66371.	2.5	33
147	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1766, 217-229.	7.4	32
148	Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. <i>Clinical Cancer Research</i> , 2018, 24, 3550-3559.	7.0	32
149	Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1860-1866.	4.1	31
150	A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4274-4282.	7.0	31
151	Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 181-188.	2.3	31
152	Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. <i>BioTechniques</i> , 2010, 48, 351-355.	1.8	31
153	Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2012, 30, 2334-2343.	2.6	31
154	The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. <i>PLoS ONE</i> , 2013, 8, e68966.	2.5	31
155	VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. , 2021, 9, e003254.		31
156	ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 817-826.	1.0	31
157	Multitargeted therapy: Can promiscuity be praised in an era of political correctness?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 150-158.	4.4	30
158	Assessment of celecoxib pharmacodynamics in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3240-3247.	4.1	30
159	Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1079-1088.	4.1	30
160	Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 3591-3599.	7.0	30
161	Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1509-1516.	4.1	29
162	Novel Microtubule-Interacting Phenoxy Pyridine and Phenyl Sulfanyl Pyridine Analogues for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5953-5957.	6.4	28

#	ARTICLE	IF	CITATIONS
163	A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5602-5609.	7.0	28
164	Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. <i>PLoS ONE</i> , 2015, 10, e0142631.	2.5	28
165	From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. <i>Journal of Cancer</i> , 2018, 9, 1978-1988.	2.5	27
166	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 515-523.	4.1	26
167	Synthesis and antitumor evaluation of benzoylphenylurea analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2213-2216.	2.2	25
168	Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids. , 2021, 9, e003213.		25
169	New scaffolds for the design of selective estrogen receptor modulators. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 3486.	2.8	24
170	Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice. <i>Clinical Cancer Research</i> , 2013, 19, 1139-1146.	7.0	24
171	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2015, 33, 710-719.	2.6	24
172	Blockade of epidermal growth factor receptor (EGFR) activity. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 179-192.	4.4	23
173	Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics. <i>Genome Medicine</i> , 2012, 13, 61.	8.2	23
174	A Prospective Pilot Study of Target-guided Personalized Chemotherapy with Intensity-modulated Radiotherapy in Patients With Early Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 117-121.	1.3	23
175	Facts and Hopes in Immunotherapy of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4606-4617.	7.0	23
176	An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. <i>Proteomics</i> , 2012, 12, 1319-1327.	2.2	22
177	Development of matrix metalloproteinase inhibitors in cancer therapy. <i>Hematology/Oncology Clinics of North America</i> , 2002, 16, 1189-1227.	2.2	21
178	Early-Onset Colorectal Cancer is an Easy and Effective Tool to Identify Retrospectively Lynch Syndrome. <i>Annals of Surgical Oncology</i> , 2011, 18, 3285-3291.	1.5	21
179	Correlation of Smad4 Status With Outcomes in Patients Receiving Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy After Resection for Pancreatic Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 458-459.	0.8	21
180	Primary Human Non-small Cell Lung and Pancreatic Tumorgraft Models—Utility and Applications in Drug Discovery and Tumor Biology. <i>Current Protocols in Pharmacology</i> , 2013, 61, Unit 14.26.	4.0	21

#	ARTICLE	IF	CITATIONS
181	A Tricin Derivative from <i>Deschampsia antarctica</i> Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 966-976.	4.1	21
182	Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 7406-7413.	7.0	20
183	Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e2023121.	5.9	20
184	New Target, New Drug, Old Paradigm. <i>Journal of Clinical Oncology</i> , 2004, 22, 2270-2272.	1.6	19
185	Design, synthesis and biological evaluation of novel riccardiphenol analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 2873-2880.	3.0	19
186	A Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer. <i>Translational Oncology</i> , 2010, 3, 373-379.	3.7	18
187	Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2010, 9, 297-304.	2.3	18
188	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 349-354.	329.8	18
189	The inverted pyramid of biomarker-driven trials. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 562-566.	27.6	17
190	Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 345-354.	2.6	17
191	The ALK translocation in advanced non-small cell lung carcinomas: preapproval testing experience at a single cancer centre. <i>Histopathology</i> , 2013, 62, 609-616.	2.9	16
192	Exploiting novel molecular targets in gastrointestinal cancers. <i>World Journal of Gastroenterology</i> , 2007, 13, 5845.	3.3	16
193	Predictors of Sensitivity and Resistance to Epidermal Growth Factor Receptor Inhibitors. <i>Clinical Lung Cancer</i> , 2004, 6, S30-S34.	2.6	15
194	Epidermal Growth Factor Receptor as a Therapeutic Target for the Treatment of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 4, 51-62.	2.3	15
195	Current Status of Mammalian Target of Rapamycin Inhibitors in Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 7, S13-S18.	2.6	15
196	Treating Cancer by Blocking Cell Signals. <i>Journal of Clinical Oncology</i> , 2005, 23, 5279-5280.	1.6	15
197	Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1895-1903.	4.1	14
198	Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. <i>Cancer Medicine</i> , 2012, 1, 207-217.	2.8	14

#	ARTICLE	IF	CITATIONS
199	Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. <i>Pharmacology Research and Perspectives</i> , 2014, 2, e00067.	2.4	14
200	Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ. <i>Breast Cancer Research</i> , 2014, 16, R76.	5.0	14
201	Elevated levels of mitochondrial CoQ10 induce ROS-mediated apoptosis in pancreatic cancer. <i>Scientific Reports</i> , 2021, 11, 5749.	3.3	14
202	MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-13.	0.8	13
203	Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 344-344.	1.6	13
204	Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue. <i>Clinical Cancer Research</i> , 2006, 12, 2158-2165.	7.0	12
205	Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. <i>Pediatric Blood and Cancer</i> , 2007, 49, 352-357.	1.5	12
206	American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 827-854.e3.	1.0	12
207	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 856, 198-204.	2.3	11
208	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2011, 29, 1057-1065.	2.6	11
209	More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer. <i>European Oncology and Haematology</i> , 2018, 14, 40.	0.0	11
210	In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent. <i>Clinical Cancer Research</i> , 2005, 11, 8503-8511.	7.0	10
211	Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. <i>Public Health Genomics</i> , 2017, 20, 81-91.	1.0	10
212	Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).. <i>Journal of Clinical Oncology</i> , 2022, 40, 518-518.	1.6	10
213	Recent advances in the pharmacological treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 423-434.	4.1	8
214	Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. <i>Nature Medicine</i> , 2014, 20, 1230-1231.	30.7	8
215	Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 1348-1354.	1.1	6
216	SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. <i>Cancers</i> , 2022, 14, 916.	3.7	6

#	ARTICLE	IF	CITATIONS
217	SEOM clinical guidelines for the treatment of pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 528-535.	2.4	5
218	From Node to Pathway Blockade: Lessons Learned From Targeting Mammalian Target of Rapamycin. <i>Journal of Clinical Oncology</i> , 2012, 30, 85-87.	1.6	5
219	Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 236-242.	1.3	5
220	Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 869, 142-145.	2.3	4
221	Methylation alterations are not a major cause of PTTG1 missregulation. <i>BMC Cancer</i> , 2008, 8, 110.	2.6	4
222	Consensus on the treatment of pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , 2009, 11, 290-301.	2.4	4
223	A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 5472-5481.	7.0	4
224	Clinical Development of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: What Lessons Have We Learned?. <i>Advances in Experimental Medicine and Biology</i> , 2008, 610, 128-143.	1.6	4
225	Saliva-Based, COVID-19 RT-PCR Pooled Screening Strategy to Keep Schools Open. <i>Disaster Medicine and Public Health Preparedness</i> , 2022, , 1-6.	1.3	4
226	Promising Developments in Targeted Therapies for non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2002, 4, 111-123.	2.6	3
227	Cetuximab in squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2006, 2, 449-457.	2.4	3
228	Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: Case Report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2009, 7, 96.	1.9	3
229	Phase II trial of BPM31510-IV plus gemcitabine in advanced pancreatic ductal adenocarcinomas (PDAC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 723-723.	1.6	3
230	Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4188-TPS4188.	1.6	3
231	Promises and pitfalls in the prediction of anti-epidermal growth factor receptor activity. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 727-735.	2.4	2
232	Tyrosine Phosphorylation Modulates the Vascular Responses of Mesenteric Arteries from Human Colorectal Tumors. <i>BioMed Research International</i> , 2013, 2013, 1-8.	1.9	2
233	Differentiated activity profile for the PD-1 inhibitor balstilimab.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5529-5529.	1.6	2
234	Abstract PO-050: Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC). <i>Cancer Research</i> , 2021, 81, PO-050-PO-050.	0.9	2

#	ARTICLE	IF	CITATIONS
235	Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 644-652.	2.6	1
236	Targeted Therapeutics in Cancer Treatment. , 2007, , 117-148.		0
237	A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 925-935.	1.4	0
238	Reply to K. de Joode et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 1093-1094.	1.6	0
239	Epidermal Growth Factor Receptor Inhibition in Non-“Small Cell Lung Cancer. <i>Translational Medicine Series</i> , 2007, , 81-96.	0.0	0
240	Targeted Therapeutics in Cancer Treatment. , 2011, , 403-461.		0
241	TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4666-TPS4666.	1.6	0